Protocol for mRNA-LNP Cytotoxicity Assays in Cancer Immunotherapy

A 1.6 MB PDF document authored by Philip Mollica and last updated on May 11, 2026. It describes a method using mRNA lipid nanoparticles to deliver reporter genes into target cells for high-throughput assessment of immune effector cell-mediated cytotoxicity. The protocol is validated for use across diverse tumor models, including primary tumor-derived models.

Use Cases

• Benchmarking the cytotoxicity of different therapeutic cell types based on the described mRNA-LNP reporter assay.
• Developing high-throughput screening pipelines for immunotherapy candidates based on the homogenous reporter expression method.
• Validating cytotoxicity assays in primary tumor models based on the protocol's reported compatibility.

Strengths

• The method is described as enabling rapid and homogenous reporter expression without compromising target cell viability.
• Results are reported to be highly consistent and comparable to those from stable cell lines.
• The protocol is licensed under CC-BY-4.0, allowing for broad reuse and adaptation.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Likely contains a detailed laboratory protocol and experimental results.

Freshness

Last updated 2026-05-11 05:25:30; freshness should be verified.